HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Launched by ZHEJIANG UNIVERSITY · Jan 7, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a new combination treatment for patients with advanced pancreatic cancer that has a specific genetic mutation known as KRAS G12D. The study will include 32 participants who will receive a treatment called HRS-4642 along with another medication called Nimotuzumab and standard chemotherapy. Researchers want to see how effective this combination is in helping patients with this challenging type of cancer.

To be eligible for the trial, participants need to be between 18 and 75 years old and have been diagnosed with metastatic pancreatic cancer, meaning the cancer has spread from the pancreas to other parts of the body. They must also have the KRAS G12D mutation in their tumor tissue and have not received any previous systemic cancer treatments for their advanced cancer. Participants can expect regular check-ups and monitoring during the study to assess their health and the effectiveness of the treatment. It’s important to note that the trial is not yet recruiting patients, but it offers hope for new treatment options for those facing advanced pancreatic cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• 1.Age: 18-75 (including 18 and 75); 2.Metastatic pancreatic cancer (from pancreatic ductal epithelium); 3.Tumor tissue contains KRAS G12D mutation; 4.No systemic antitumor therapy in advanced stage; if previous neoadjuvant / adjuvant therapy, last treatment should be over 6 months; 5.At least one measurable lesion according to the RECIST v1.1 criteria; 6.The ECOG (Eastern Cooperative Oncology) score was 0-1; 7.Expected survival period of 3 months; 8.The functions of vital organs meets the following requirements (any blood components, cell growth factors are not allowed 2 weeks prior to enrollment):
• • 1. Neutrophil count≥1.5×10\^9 / L;
• • 2. Platelet≥100×10\^9 / L;
• • 3. Hemoglobin≥100 g / L;
• • 4. Serum albumin≥30 g / L;
• • 5. Total bilirubin≤1.5×ULN; ALT, AST≤3×ULN and ALP≤2.5×ULN; if the patient has liver metastasis, ALT, ALT and AST≤5×ULN; if the patient has liver or bone metastasis, ALP≤5×ULN;
• • 6. Creatinine clearance≥50 mL/min or serum creatinine ≤1.5×ULN;
• • 7. Urinary protein \<2+; if urine protein≥2+, an additional 24 hours urine protein quantification should be tested, and if 24 hours urine protein quantification \<1g can be enrolled;
• • 8. ECG: QTcF≤450 ms (male), QTcF≤470 ms (female);
• • 9. Cardiac color ultrasound: LVEF (left ventricular ejection fraction) ≥50%; 9.Women of childbearing age must have a blood pregnancy test within 7 days before enrollment, the result should be negative and must be non-lactating and should be willing to use appropriate contraception during the trial and within 6 months of treatment. For men, surgical sterilization or consent to use appropriate contraception during the study and within 6 months after completion of treatment.
• • 10.Volunteer to participate in the study and sign the informed consent form, good compliance, agreed to cooperate with the follow-up.
• Exclusion Criteria:
• 1.Previous treatment:
• • 1. Previous treatment of targeted therapy against KRAS G12D.
• • 2. Previous targeted therapy against EGFR.
• • 3. Received major surgery or major trauma within 4 weeks before enrollment, or palliative local treatment (including but not limited to palliative radiotherapy, interventional therapy) within 2 weeks prior to enrollment.
• • 4. Have received any other clinical study medication within 4 weeks before enrollment, except for an observational (non-interventional) clinical study or interventional clinical study follow-up.
• • (5)14 days before enrollment with drugs that strongly inhibit or induce the hepatic drug-metabolizing enzymes CYP3A4 or CYP2C8.
• • 2.The presence of a central nervous system (CNS) metastases. 3.Acute or chronic pancreatitis requiring clinical intervention. 4.Symptoms and signs of gastrointestinal obstruction or obstruction within 6 months before initiation of study treatment but can be screened if surgery is performed and the obstruction is completely resolved.
• • 5.Within 2 weeks prior to enrollment, there is a third space effusion (such as a large amount of pleural fluid, ascites, etc.) that can not reach the stable state (no intervention treatment is needed after the removal of the drainage tube), and only a small amount of effusion on imaging and without clinical symptoms can be enrolled.
• • 6.Severe infection occurred within 4 weeks before enrollment, such as severe pneumonia, bacteremia, infectious complications, requiring hospitalization; fever of unknown cause\> 38.5℃ within 2 weeks before enrollment (fever caused by the tumor according to the investigator); 2 weeks of enrollment (except in cases of prophylactic antibiotics).
• • 7.Severe cardiovascular and cerebrovascular disease. 8.Patients with known or suspected interstitial pneumonia except only interstitial changes on imaging.
• • 9.Prior history of clear neurological or psychiatric disorders, including epilepsy and dementia.
• • 10.Presence of non-healing wounds (severe, non-healing or split), uncured fractures.
• • 11.Adverse events due to prior treatment prior to enrollment did not return to NCI-CTCAE level 1 (except for alopecia and enrollment criteria; except AEs not affecting the study medication).
• • 12.Malignant tumors other than the primary tumor within the 5 years before enrollment, except those with low risk of metastasis and death: adequately treated cervical carcinoma in situ, skin basal cells or squamous cell carcinoma, etc.
• • 13.Combined with active hepatitis B (hepatitis B surface antigen positive and HBV DNA 500 IU / mL), hepatitis C (hepatitis C antibody positive, and HCV-RNA above the lower limit of detection of the analytical method). Those known to have acquired immunodeficiency syndrome or test positive for HIV, and those infected with active syphilis. Subjects with active tuberculosis or a history of active tuberculosis infection within 48 weeks before screening, with or without treatment.
• • 14.Known to be allergic to any component of HRS-4642; allergic to any component of nytuzumab or other monoclonal antibody / fusion proteins, albumin paclitaxel, gemcitabine.
• • 15.By the investigator, the patient had other factors that might affect the study results or lead to the forced termination of the study.